189 related articles for article (PubMed ID: 21701776)
1. Transforming growth factor-β-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathway.
Wen G; Hong M; Li B; Liao W; Cheng SK; Hu B; Calaf GM; Lu P; Partridge MA; Tong J; Hei TK
Int J Oncol; 2011 Oct; 39(4):1001-9. PubMed ID: 21701776
[TBL] [Abstract][Full Text] [Related]
2. The role of TGFBI in mesothelioma and breast cancer: association with tumor suppression.
Li B; Wen G; Zhao Y; Tong J; Hei TK
BMC Cancer; 2012 Jun; 12():239. PubMed ID: 22695319
[TBL] [Abstract][Full Text] [Related]
3. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
Jagadeeswaran R; Ma PC; Seiwert TY; Jagadeeswaran S; Zumba O; Nallasura V; Ahmed S; Filiberti R; Paganuzzi M; Puntoni R; Kratzke RA; Gordon GJ; Sugarbaker DJ; Bueno R; Janamanchi V; Bindokas VP; Kindler HL; Salgia R
Cancer Res; 2006 Jan; 66(1):352-61. PubMed ID: 16397249
[TBL] [Abstract][Full Text] [Related]
4. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
Bonelli MA; Digiacomo G; Fumarola C; Alfieri R; Quaini F; Falco A; Madeddu D; La Monica S; Cretella D; Ravelli A; Ulivi P; Tebaldi M; Calistri D; Delmonte A; Ampollini L; Carbognani P; Tiseo M; Cavazzoni A; Petronini PG
Neoplasia; 2017 Aug; 19(8):637-648. PubMed ID: 28704762
[TBL] [Abstract][Full Text] [Related]
5. ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.
Tumbarello DA; Temple J; Brenton JD
Mol Cancer; 2012 May; 11():36. PubMed ID: 22640878
[TBL] [Abstract][Full Text] [Related]
6. Novel prognostic marker TGFBI affects the migration and invasion function of ovarian cancer cells and activates the integrin αvβ3-PI3K-Akt signaling pathway.
Wang H; Xu YH; Guo Y
J Ovarian Res; 2024 Feb; 17(1):50. PubMed ID: 38395907
[TBL] [Abstract][Full Text] [Related]
7. mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids.
Wilson SM; Barbone D; Yang TM; Jablons DM; Bueno R; Sugarbaker DJ; Nishimura SL; Gordon GJ; Broaddus VC
Am J Respir Cell Mol Biol; 2008 Nov; 39(5):576-83. PubMed ID: 18511708
[TBL] [Abstract][Full Text] [Related]
8. GAS5 long non-coding RNA in malignant pleural mesothelioma.
Renganathan A; Kresoja-Rakic J; Echeverry N; Ziltener G; Vrugt B; Opitz I; Stahel RA; Felley-Bosco E
Mol Cancer; 2014 May; 13():119. PubMed ID: 24885398
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Expression of TGFBI Promotes the Proliferation and Migration of Glioma Cells.
Guo SK; Shen MF; Yao HW; Liu YS
Cell Physiol Biochem; 2018; 49(3):1097-1109. PubMed ID: 30196284
[TBL] [Abstract][Full Text] [Related]
10. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
[TBL] [Abstract][Full Text] [Related]
11.
Canales J; Valenzuela M; Bravo J; Cerda-Opazo P; Jorquera C; Toledo H; Bravo D; Quest AF
Front Cell Infect Microbiol; 2017; 7():92. PubMed ID: 28401064
[No Abstract] [Full Text] [Related]
12. Discoidin domain receptor 1 contributes to tumorigenesis through modulation of TGFBI expression.
Rudra-Ganguly N; Lowe C; Mattie M; Chang MS; Satpayev D; Verlinsky A; An Z; Hu L; Yang P; Challita-Eid P; Stover DR; Pereira DS
PLoS One; 2014; 9(11):e111515. PubMed ID: 25369402
[TBL] [Abstract][Full Text] [Related]
13. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells.
Xu Z; Zhang Y; Jiang J; Yang Y; Shi R; Hao B; Zhang Z; Huang Z; Kim JW; Zhang G
BMC Cancer; 2010 Apr; 10():161. PubMed ID: 20423485
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
[TBL] [Abstract][Full Text] [Related]
16. High stromal transforming growth factor β-induced expression is a novel marker of progression and poor prognosis in gastric cancer.
Suzuki M; Yokobori T; Gombodorj N; Yashiro M; Turtoi A; Handa T; Ogata K; Oyama T; Shirabe K; Kuwano H
J Surg Oncol; 2018 Nov; 118(6):966-974. PubMed ID: 30260476
[TBL] [Abstract][Full Text] [Related]
17. Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway.
Wu XL; Wang LK; Yang DD; Qu M; Yang YJ; Guo F; Han L; Xue J
J Cell Biochem; 2018 Feb; 119(2):2356-2367. PubMed ID: 28884839
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
20. TGF-β-induced (TGFBI) protein in melanoma: a signature of high metastatic potential.
Lauden L; Siewiera J; Boukouaci W; Ramgolam K; Mourah S; Lebbe C; Charron D; Aoudjit F; Jabrane-Ferrat N; Al-Daccak R
J Invest Dermatol; 2014 Jun; 134(6):1675-1685. PubMed ID: 24499734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
